| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
Cibinqo is owned by Pfizer.
Cibinqo contains Abrocitinib.
Cibinqo has a total of 3 drug patents out of which 0 drug patents have expired.
Cibinqo was authorised for market use on 14 January, 2022.
Cibinqo is available in tablet;oral dosage forms.
Cibinqo can be used as treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable.
Drug patent challenges can be filed against Cibinqo from 14 January, 2026.
The generics of Cibinqo are possible to be released after 19 February, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2027 |
| New Patient Population(NPP) | Feb 09, 2026 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 14 January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
CIBINQO family patents
